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Background
Systemic Lupus Erythematosus (SLE) is a multisystem
autoimmune connective tissue disease that has a strong
female predominance (9:1) seen especially in women of
child-bearing years [1]. Although the exact mechanisms
of disease are not completely understood, the role of
dysregulated microRNA (miRNA) has been implicated
in the pathogenesis of SLE [2]. Clinically, the disease is
unpredictable, with the current therapy for symptomatic
patients associated with undesirable side effects and
toxicity affecting multiple organs [3]. Therefore, in order
to bridge the gap between disease and cure, an in depth
understanding of disease pathogenesis is required to
manufacture medications that tackle the underlying
cause of the disease. In this study, we set out to validate
differentially expressed miRNAs in SLE patient mono-
cytes versus healthy controls, previously identified in a
microRNA screen carried out in the group. Furthermore
we aim to perform bioinformatics analysis to predict
potential gene targets for these miRNAs that may play a
role in the disease pathogenesis.
Methods
RNA was extracted from monocytes from SLE patients
and healthy controls previously collected in the laboratory.
Bioinformatics analysis was undertaken to identify poten-
tial genes targeted by miRNAs of interest. The primers
specific to the miRNAs were designed and optimised fol-
lowing which gene induction of miRNAs was determined
by PCR. In order to investigate the expression of miRNAs,
densitometric analysis of the gel electrophoresis was
determined.
Results
In the study, the expression of miRNA-107 and miRNA-
132 were investigated. The expression of miR-107 was sig-
nificantly greater in SLE patients than in healthy controls
(p<0.00362), whilst there were no appreciable differences
in miRNA-132 expression in SLE patients and healthy
controls. SMURF1 and SOCS5 were identified as potential
genes targeted by miRNA-107, however no significant
change in expression in either genes were observed in SLE
patients versus controls.
Conclusions
There was a significant increase in the expression levels of
miRNA-107 in SLE patients, while no significant changes
in miRNA-132 was demonstrated. Further investigation
into potential gene targets for miR-107 is required in
order to understand the pathological importance of dysre-
gulation of this miRNA in SLE and its therapeutic
implications
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